Cancer Institute And Hospital, Chinese Academy Of Medical Sciences
Clinical trials sponsored by Cancer Institute And Hospital, Chinese Academy Of Medical Sciences, explained in plain language.
-
Radiation boost tested to stop breast Cancer's return
Disease control OngoingThis large study is testing whether adding radiation to a specific set of lymph nodes inside the chest wall helps prevent breast cancer from coming back in high-risk patients. It involves 2,400 people who have already had surgery and chemotherapy. Researchers will compare two rad…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for tough blood disorder: Three-Drug combo enters trial
Disease control OngoingThis study is testing whether a combination of three drugs—selinexor, thalidomide, and dexamethasone—can help control Langerhans cell histiocytosis (LCH) in adults whose disease has come back or hasn't responded to previous treatments. It will involve about 40 participants at mul…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Scientists test gentler combo to tame lymphoma
Disease control OngoingThis study is testing a new combination of drugs for people with a type of blood cancer called marginal zone lymphoma who have not yet received treatment. The goal is to see if this regimen can effectively control the disease while causing fewer severe side effects than current s…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Researchers analyze best treatment path for advanced stomach cancer
Disease control OngoingThis study looks back at 300 patients with advanced stomach or gastroesophageal junction cancer who received treatment before and after surgery. Researchers are analyzing which treatment approaches led to the best long-term survival and whether tumor response to pre-surgery treat…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat blood cancer: experimental combo therapy enters testing
Disease control OngoingThis study is testing whether adding a new immunotherapy drug called glofitamab to a standard chemotherapy regimen (GemOx) can help control a fast-growing type of blood cancer called diffuse large B-cell lymphoma (DLBCL) in patients whose cancer did not fully respond to their fir…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Breakthrough cancer treatment goes on trial in china
Disease control OngoingThis study is testing whether adding a more affordable immunotherapy drug called toripalimab to standard chemoradiation treatment can better control high-risk cervical cancer. It will involve 57 patients with advanced cervical cancer who have not received prior treatment. The mai…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New hope for Tough-to-Treat lung tumors
Disease control OngoingThis study is testing whether adding an immunotherapy drug called toripalimab to standard chemotherapy and radiation works better for people with large, advanced non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can better contro…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Breast cancer patients try 2-Week radiation instead of 6 weeks
Disease control OngoingThis study is testing whether a shorter, more targeted radiation treatment can effectively prevent cancer from returning in early-stage breast cancer patients. The treatment delivers radiation only to the area where the tumor was removed, over just two weeks instead of the typica…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
AI could predict bladder cancer treatment target without extra biopsy
Diagnosis ENROLLING_BY_INVITATIONThis study is testing a new artificial intelligence (AI) tool designed to predict a specific cancer marker called HER2 in bladder cancer. The AI analyzes a patient's existing MRI scans and digital pathology images to see if it can accurately determine HER2 status, which helps gui…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Diagnosis
Last updated Apr 01, 2026 14:41 UTC
-
Simple blood test could predict Lymphoma's return
Knowledge-focused OngoingThis study aims to see if tracking tiny pieces of tumor DNA in the blood can help predict how well lymphoma treatment is working and whether the cancer might come back. Researchers will collect blood samples from 60 patients with B-cell non-Hodgkin lymphoma before, during, and af…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Massive 10,000-Patient study seeks best Post-Surgery treatment path for lung cancer
Knowledge-focused OngoingThis study looks back at the medical records of 10,000 lung cancer patients who received immunotherapy before surgery. Researchers want to understand which follow-up treatments after surgery lead to the best survival rates and identify markers that predict which patients need add…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Mar 18, 2026 14:41 UTC